The Valley Desk

ArticleBMJ oncologyPublished

Efficacy of nivolumab plus relatlimab versus BRAF/MEK inhibitors for first-line treatment of BRAF-mutant advanced melanoma: A matching-adjusted indirect comparison

Read the publication ↗ Open access copy ↗

Regional connection

Verified An author affiliation on the Europe PMC record names Bristol Myers Squibb. Affiliation source

Publication record

Type
Article
Venue
BMJ oncology
Published
Subject terms
Immunotherapy; Skin Cancer (Malignant Melanoma)
PubMed ID
41971757
PubMed Central ID
PMC13064201
Open access
Yes, open
Added to directory
Source checked

Report a correction or request removal